Expiration date: 01/2026
Clinical Pharmacology
Pharmacotherapeutic group: antiviral, immunomodulatory agent
ATX code J05AX, L03A
PHARMACOLOGICAL PROPERTIES
Pharmacodynamics
Alloferon is an oligopeptide. By the nature of the pharmacological action, it is most similar to interferon alpha. Alloferon is an effective inducer of endogenous interferon synthesis and an activator of the natural killer system, and is able to stimulate the recognition and lysis of defective cells by cytotoxic lymphocytes. The experiments demonstrated high efficacy against infections caused by influenza A and B viruses, hepatitis B and C, herpes types 1 and 2, and human papilloma. Alloferon does not have general toxicity, allergenic properties, mutagenic and carcinogenic effects, does not have an embryotoxic effect and does not affect the reproductive function.
Pharmacokinetics
It quickly penetrates into the blood, where it interacts with immunocompetent cells, after which the determination of the concentration of Alloferon is difficult due to the close structural similarity of its metabolites with serum proteins. An increase in the concentration of interferon was observed 2 hours after administration of the drug and remained at a high level (2-2. 5 times higher than the usual background) for 6-8 hours with the achievement of the initial values by the end of the day. Increased functional activity of natural killers was observed within 7 days after administration of the drug.
Release form and composition
Per 1 ampoule: Alloferon [Histidyl-glycyl-valyl-seryl-glycyl-histidyl-glycyl-glutaminyl-histidyl-glycyl-valyl-histidyl-glycine] 1.0 mg
Special instructions
Treatment is recommended to begin at the very first signs of the disease, with hepatitis B-no later than the 7th day from the beginning of the appearance of jaundice.
Impact on the ability to drive a car and work with equipment
In case of dizziness, it is necessary to refrain from driving and working with equipment.
Interaction
In the treatment of chronic recurrent genital herpes, it can be prescribed in combination with acyclovir and its derivatives (the drugs have a different mechanism of action and complement each other in the treatment of viral infection). In acute hepatitis B, the drug is prescribed against the background of generally accepted basic therapy.
Interaction with other drugs was not detected.
Overdose
To date, no cases of drug overdose have been established.
How to take, course of administration and dosage
The drug is administered subcutaneously.
The standard course of treatment for herpes relapse includes injections of the drug at a dose of 1 mg every other day, for a total of 3 injections.
In moderate forms of acute hepatitis B, the drug is administered after verification of the diagnosis at a dose of 1 mg 3 times a week for 3 weeks (a total of 9 injections).
To prepare a solution for injection, use 1 ml of 0.9% sodium chloride solution as a solvent.
Contraindications
Hypersensitivity, pregnancy and breastfeeding (for the duration of treatment is discontinued), severe autoimmune diseases.
Children's age.
Allokin-alpha indications for use
Chronic recurrent herpes types 1 and 2, as part of complex therapy in the moderate (jaundice) form of acute hepatitis B.
Side effects
In some cases, weakness, dizziness, the formation of new elements of the rash (with herpes infection) are possible.
Storage conditions
In a dry place, protected from light, at a temperature of 2-8 °C
By prescription Yes
Expiration date
2 years. Do not use after the expiration date.
